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Dystroglycanopathies are a clinically and genetically diverse group of recessively inherited conditions ranging from the most severe
of the congenital muscular dystrophies, Walker–Warburg syndrome, to mild forms of adult-onset limb-girdle muscular dystrophy.
Their hallmark is a reduction in the functional glycosylation of a-dystroglycan, which can be detected in muscle biopsies. An
important part of this glycosylation is a unique O-mannosylation, essential for the interaction of a-dystroglycan with extracellular
matrix proteins such as laminin-a2. Mutations in eight genes coding for proteins in the glycosylation pathway are responsible for
50% of dystroglycanopathy cases. Despite multiple efforts using traditional positional cloning, the causative genes for unsolved
dystroglycanopathy cases have escaped discovery for several years. In a recent collaborative study, we discovered that
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loss-of-function recessive mutations in a novel gene, called isoprenoid synthase domain containing (ISPD), are a relatively common
cause of Walker–Warburg syndrome. In this article, we report the involvement of the ISPD gene in milder dystroglycanopathy
phenotypes ranging from congenital muscular dystrophy to limb-girdle muscular dystrophy and identified allelic ISPD variants in
nine cases belonging to seven families. In two ambulant cases, there was evidence of structural brain involvement, whereas in seven,
the clinical manifestation was restricted to a dystrophic skeletal muscle phenotype. Although the function of ISPD in mammals is not
yet known, mutations in this gene clearly lead to a reduction in the functional glycosylation of a-dystroglycan, which not only causes
the severe Walker–Warburg syndrome but is also a common cause of the milder forms of dystroglycanopathy.
Keywords: congenital muscular dystrophy; limb-girdle muscular dystrophy; dystroglycan; laminin; isoprenoid synthase
Abbreviations: CDP-ME = 4-diphosphocytidyl-2-methyl-D-erythritol synthase; LGMD = limb-girdle muscular dystrophy
Introduction
Congenital muscular dystrophies and limb-girdle muscular dystro-
phies (LGMDs) are characterized by hypotonia, muscle weakness,
variable appearance of contractures and dystrophic changes on
skeletal muscle biopsy. Although the congenital muscular dystro-
phies present either congenitally or during the first 6 months of
life, the LGMDs present in late childhood, adolescence or adulthood
(Voit, 1998; Bonnemann and Finkel, 2002). A number of genetically
distinct entities have been identified within the congenital muscular
dystrophies and LGMDs that are classified according to clinical and
pathological criteria. An important subgroup, collectively known as
the ‘dystroglycanopathies’, is associated with a reduction in the
functional glycosylation of -dystroglycan (Muntoni and Voit,
2004). Dystroglycan is composed of two subunits,  and b, which
are post-translationally cleaved to give rise to a transmembrane (b)
and external membrane protein (), which is heavily O-glycosylated
(Stalnaker et al., 2011). An important part of this glycosylation is a
unique O-mannosylation sugar moiety that is involved in the inter-
action of -dystroglycan with extracellular matrix proteins, such as
laminin, agrin, perlecan, neurexin and pikachurin (Kanagawa and
Toda, 2006; Waite et al., 2012). Mutations in eight genes coding
for putative or demonstrated glycosyltransferases or other proteins
involved in the -dystroglycan glycosylation pathway have been
identified in the dystroglycanopathies: protein O-mannosyltransfer-
ase 1 (POMT1; OMIM 607423) (Beltran-Valero de Bernabe et al.,
2002), protein O-mannosyltransferase 2 (POMT2; OMIM 607439)
(van Reeuwijk et al., 2005), protein O-mannose b-1, 2-N-acetyl-
glucosaminyltransferase (POMGNT1; OMIM 606822) (Yoshida
et al., 2001), fukutin (FKTN; OMIM 607440) (Kobayashi et al.,
1998), fukutin-related protein (FKRP; OMIM 606596)
(Brockington et al., 2001a), like-acetylglucosaminyltransferase
(LARGE; OMIM 603590) (Longman et al., 2003) and dolichyl-
phosphate mannosyltransferase polypeptide 3 (DPM3; OMIM
605951) (Lefeber et al., 2009). Recently, a missense mutation in
the DPM3 gene was reported in a single patient with LGMD and
stroke (Lefeber et al., 2009), and mutations in dolichol kinase
(DOLK; OMIM 610746) have been reported in children with
severe cardiomyopathy with reduced -dystroglycan glycosylation
and elevated serum creatine kinase levels (Lefeber et al., 2011).
Interestingly, a single case was found to have a primary dys-
troglycanopathy due to a homozygous missense mutation at the
N-terminus of dystroglycan 1 (DAG1; OMIM 128239) (Hara
et al., 2011). The phenotypic spectrum arising from mutations in
these dystroglycanopathy genes is extremely wide and includes
(i) forms of congenital onset weakness and severe structural brain
abnormalities, including Walker–Warburg syndrome (OMIM
236670; Walker, 1942; Warburg, 1971), muscle–eye–brain disease
(OMIM 253280; Raitta et al., 1978) and Fukuyama congenital
muscular dystrophy (OMIM 253800; Fukuyama, 1960); (ii) forms
with congenital onset of weakness ranging from absent to severe
brain involvement, including congenital muscular dystrophy type 1C
(MDC1C; OMIM 606612) (Brockington et al., 2001a) and type 1D
(MDC1D; OMIM 608840) (Longman et al., 2003); and (iii) forms
with later-onset limb-girdle weakness associated with mental re-
tardation and microcephaly but without structural brain defects as
seen in LGMD type 2K (LGMD2K; OMIM 609308) (Dincer et al.,
2003), and the mildest variants with no brain involvement, such as
in LGMD type 2I (LGMD2I; OMIM 607155) (Brockington et al.,
2001b). Mutations in these genes mentioned above are responsible
for 50–60% of the cases classified as dystroglycanopathy (Godfrey
et al., 2007; Mercuri et al., 2009; Messina et al., 2010; Devisme
et al., 2012). Using traditional positional cloning, the causative
genes for the unsolved dystroglycanopathy cases had escaped dis-
covery. Cirak et al. (2009) mapped a novel disease locus to chromo-
some 7p21 in a family with loss of -dystroglycan glycosylation.
Recently we discovered that bi-allelic loss-of-function mutations in
the isoprenoid synthase domain containing (ISPD) gene, which maps
to chromosome 7p21, are a frequent cause of Walker–Warburg syn-
drome (Willer et al., 2012). We now report the identification of nine
patients from seven families who have mutations in ISPD, with
phenotypes ranging from congenital muscular dystrophy to
LGMD. These families included the original family mapped to 7p21
(Cirak et al., 2009). Here we present the clinical, genetic and patho-
logical features of the milder phenotypic spectrum related to muta-
tions in ISPD.
Materials and methods
Subjects and clinical assessments
The study was approved by the Institutional Ethical Review Board of
the University College London Institute of Child Health and Great
Ormond Street Hospital in the UK, the Ethical Review Board of the
University of Duisburg-Essen in Germany and the Human Use
Committee at the University of Iowa. Informed consent was obtained
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from the parents. The consent and local review board approval were in
accordance with the UK10K project ethical framework (http://www.
uk10k.org/ethics.html).
A three-generation family of Turkish origin with multiple loops of
consanguinity demonstrating autosomal recessive inheritance was re-
cruited (Supplementary Fig. 1). All three affected children and three
unaffected siblings were examined, and serum creatine kinase levels
were assessed in all siblings. The family was followed-up for 410
years, with the annual clinic visits at the University Children’s
Hospital Essen in Germany.
Forty-seven patients with the clinical and pathological diagnosis of a
dystroglycanopathy were recruited at the Dubowitz Neuromuscular
Centre at the Great Ormond Street Hospital London, UK. Genomic
DNA was extracted from blood using standard procedures. In all pa-
tients, mutations in POMT1, POMT2, POMGNT1, FKRP, FKTN and
LARGE were excluded by Sanger sequencing. Of these 47 cases, 14
underwent initial exome sequencing, and an additional 33 were Sanger
sequenced after the discovery of the ISPD gene mutations. Apart from
the three cases of the Turkish family reported in this study, all other 44
cases were unrelated.
Histology and immunohistochemistry
Immunohistochemical studies were performed as described previously
(Dubowitz and Sewry, 2007). Muscle biopsies were obtained using
standard techniques and mounted in optimal cutting temperature
medium, and were then frozen by immersion in isopentane cooled
in liquid nitrogen. Unfixed, frozen serial sections (7 mm) were incu-
bated with primary antibodies for 1 h at room temperature, followed
by three washes in PBS. Sections were then incubated with
anti-mouse– or anti-rabbit–biotinylated IgG or IgM-biotinylated sec-
ondary antibodies (General Electric Healthcare, 1:200) for 30 min at
room temperature. After washing, muscle sections were incubated
with streptavidin conjugated to Alexa Fluor 594 (Invitrogen,
1:1000) for 15 min at room temperature, and then washed
and mounted using Hydromount mounting medium (National
Diagnostics). Primary antibodies used were mouse monoclonal:
-dystroglycan IIH6 (clone IIH6C4, 1:200), -dystroglycan VIA4-1
(Merck Millipore, 1:50), b-dystroglycan (clone 43dag1/8d5, Leica,
1:20), laminin-2 (MAB1922 clone 5H2 Merck Millipore, 1:4000) to
the 80-kDa C-terminal fragment, laminin-1 (LT3 Merck Millipore,
1:4000), laminin-b2 (gift from Dr Ulla Wewer, Clone S5F11, 1:500)
(Wewer et al., 1997) and b-spectrin (Leica, 1:20), rat monoclonal
laminin-2 (clone 4H8–2 Alexis Corporation, 1:100) N-terminal frag-
ment, goat polyclonal core -dystroglycan (GT20ADG, 1:20). Sections
were evaluated using a Leica DMR microscope interfaced to
MetaMorph (Molecular Devices). Muscle biopsies from Cases 1, 2, 8
and 9 were processed and reported in the diagnostic pathology units
elsewhere. The muscle biopsy from Case 5 was evaluated according to
the methods described by Willer et al. (2012).
Western blot and immunoblot
Western blot of the available muscle biopsy specimens was performed
as described by Brockington et al. (2010). The following primary anti-
bodies were used for the western blot of the muscle biopsies from
Cases 4 and 7: anti-mouse -dystroglycan IIH6 (Merck Millipore, cata-
logue 05-593), -dystroglycan VIA4-1 (Leica, 1:50) and anti-mouse
b-dystroglycan (Leica). Further experimental details are outlined in
the Supplementary material. The muscle biopsy of Case 5 was studied
using wheat germ agglutinin-enriched muscle homogenates as
described previously (Michele et al., 2002). Immunoblots were done
on polyvinylidene difluoride membranes as described earlier (Michele
et al., 2002). The following antibodies were used for Case 5: the
monoclonal antibodies to the fully glycosylated form of -dystroglycan
(IIH6 and VIA4) (Ervasti and Campbell, 1991) and -dystroglycan
(AP83) (Duclos et al., 1998). Shp5 (core--DG) from sheep antiserum
was raised against the dystrophin–glycoprotein complex in its entirety
and purified against a hypoglycosylated full-length -DG–human
IgGFc fusion protein (Kunz et al., 2001). Blots were developed by
horseradish peroxidase enhanced chemiluminescence (Pierce).
Exome sequencing and data processing
Genomic DNA (1–3 mg) was sheared to 100–400 bp using a Covaris E210
or LE220 ultarsonicator. Sheared DNA was subjected to Illumina
paired-end DNA library preparation and enriched for target sequences
(Agilent Technologies; Human All Exon 50 Mb-ELID S02972011) accord-
ing to the manufacturer’s recommendations (Agilent Technologies;
SureSelectXT Automated Target Enrichment for Illumina Paired-End
Multiplexed Sequencing). Enriched libraries were sequenced using the
HiSeq
TM
platform (IIIumina) as paired-end 75-bp reads according to the
manufacturer’s protocol. Sequencing reads that failed quality filtering
were removed using the Illumina Genome Analyser Pipeline. The mean
coverage of the exomes was 74 times with the descriptive exome, and
statistical data are presented in Supplementary Table 1.
The Burrows–Wheeler Aligner (Li and Durbin, 2009) was used for
alignment to the human reference genome build UCSC hg19, followed
by the removal of polymerase chain reaction (PCR) duplicates using
Picard (http://picard.sourceforge.net). The variant calling was per-
formed in target  100-bp regions. For the variant calling, SAMtools
(version 0.1.17) (Li et al., 2009) and Genome Analysis Toolkit (GATK)-
Unified Genotyper (version 1.1-5) (McKenna et al., 2010) were used.
Base quality recalibration and indel realignment were done with the
help of GATK (DePristo et al., 2011). For each exome sample, variant
sites (single nucleotide polymorphisms and indels) are called using the
GATK-Unified Genotyper, and marked up with single nucleotide poly-
morphism database (dbSNP)132 rs-ids, GATK variant filtration applied
(soft filter), including an indel mask consisting of 1000 Genomes pilot
indels. Variants were assigned to quality tranches by GATK. The vari-
ants called by each of the callers were filtered separately using
vcf-filter. For each sample, the resulting gatk.vcf and mpileup.vcf
files were merged using vcf-isec. GATK annotations are preferred if
sites are in both call sets. The variant calls were annotated using
vcf-annotate for the following information: earliest version of dbSNP
containing this call, dbSNP 132 rsIDs and 1000 Genomes population
allele frequencies. The 1000 Genomes frequencies are taken from the
June 2011 data release (http://www.1000genomes.org/data).
Additionally, a number of functional scores were annotated to aid
the filtering of variants. Further details of the variant calling and an-
notation procedures are listed in the Supplementary material.
Variant filtering
We used an in-house software to dynamically filter candidate variants
on the basis of the autosomal recessive inheritance. Depending on the
pedigree structure, we looked for either homozygous or two functional
heterozygous changes in the same gene. The filtering at the ISPD locus
was stringent, excluding the following variants: present in dbSNP132,
present in 1000 Genomes, synonymous and other non-coding variants
apart from essential splice site changes and not present in remaining
UK10K rare disease cohort (322 exomes at the time of the analysis).
None of the variants were present in the National Heart, Lung, and
Blood Institute (NHLBI) Exome Sequencing Project database.
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Copy number analysis
We used ExomeDepth (Plagnol et al., 2012, available at http://cran.r-
project.org/) to fit a robust beta-binomial model to the read count
data. By comparing read count between the test sample and additional
exome samples from the same batch, this software predicts the
expected read count. Deviations from this expectation are used to
call copy number variants. ExomeDepth was run on all 14 cases
who were whole-exome sequenced.
Experimental copy number validation
Quantitative fluorescent PCR analysis was performed as described
previously (Yau et al., 1996). A single quantitative fluorescent PCR
assay was designed to determine the copy number of exons 2, 3, 4,
5, 6, 7, 8, 9 and 10 of the ISPD gene by amplifying nine amplicons
in a single 20-ml reaction using 6-FAM (Life Technologies) labelled for-
ward primers and non-labelled reverse primers (primers and amplifica-
tion conditions available on request). Fluorescent amplicons
were analysed on an ABI 3730 DNA Analyzer (Applied Biosystems),
and the data were then analysed with GeneMarker (SoftGenetics).
The relative copy number of each exon was determined using dosage
quotients as previously described (Yau et al., 1996).
Sanger sequencing
All exons and 50 bp of the flanking introns of the ISPD gene
were sequenced from genomic DNA extracted from blood using
standard protocols. PCR products were amplified using standard tech-
niques and purified for sequence analysis with ExoI/shrimp alkaline
phosphatase. Bi-directional fluorescent sequencing analysis was per-
formed by the UCL genomic services using BigDye v.1.1 Cycle
Sequencing Kits (Applied Biosystems), which were analysed on an
ABI 3730XL DNA Analyzer (Applied Biosystems) after purification
using ethanol precipitation. Primer sequences are available on request.
Each sequence was analysed visually using the Lasergene Seqman
(DNASTAR) software.
Results
Clinical findings
We have identified nine cases from seven families with pheno-
types milder than Walker–Warburg syndrome and ISPD mutations.
Clinical features are summarized in Table 1, while a more de-
tailed clinical case description is provided in the Supplementary
material.
Cases 1, 2, 3, 5 and 7 have an LGMD-like phenotype without
brain involvement (Fig. 1). Each of these five patients presented
in early childhood with difficulty in walking and evidence of a
Gowers’ sign. Case 3 is currently 4 years old and ambulant, but
with proximal weakness and evidence of a Gowers’ sign. In Cases
1, 2, 3, 5 and 7, gross motor function improved until the age of
4 years, and all acquired the ability to climb stairs. Progression
of proximal muscle weakness, however, led to loss of independ-
ent ambulation by the age of 12 years in Cases 1, 2 and 7. In
Case 5 (Fig. 1), hypotonia was noted during the first year of life,
but the subsequent disease course has been LGMD-like, making
the overall phenotype intermediate congenital muscular
dystrophy/LGMD-like. Generalized muscle hypertrophy was
common, which included tongue hypertrophy in Cases 1 and 2
(Fig. 1). Case 8 is currently 10 years old and has a milder LGMD
phenotype with learning difficulties. She is fully ambulant and can
run slowly despite proximal muscle weakness. Case 4, currently
aged 7 years, has a congenital muscular dystrophy phenotype
without brain involvement. She never achieved independent
walking or standing, but can use a self-propelling wheelchair
and bottom shuffles.
In terms of cardiopulmonary involvement, a mild decrease
in heart function with a fractional shortening of 27% was docu-
mented in Case 1 at the age of 19 years, for which isoprolol
was started. The patient’s forced vital capacity was almost
normal, at 85% predicted. Case 2 had mildly reduced left
ventricular heart function noted at the age of 12, for which treat-
ment with captopril was started. Case 7 developed nocturnal
hypoventilation at the age of 18 years. Her ECG showed
a reduced left ventricular ejection fraction of 45%. Case 9
developed respiratory insufficiency at the age of 23 years, with
a forced vital capacity of 49% predicted. Her ECG revealed normal
heart function.
Cases 6 and 9 (Fig. 1) have overlapping clinical features be-
tween congenital muscular dystrophy and LGMD and, for this
reason, will be presented in more detail. Both presented in the
first year of life with hypotonia and eye and brain involvement
(with structural cerebellar and brainstem MRI abnormalities), but
followed a relatively mild LGMD-like disease course. As their pre-
senting symptoms were that of feeding and eye movement prob-
lems without weakness, this suggests that their early presentations
were secondary to the CNS brain involvement, and not the sever-
ity of their muscle involvement. Case 6 is a boy aged 8.5 years. He
presented at 6 months with a squint and was subsequently diag-
nosed with oculomotor apraxia, with difficulties in initiating sac-
cades, a choroidal coloboma and severe myopia. Multiple
cerebellar cysts were seen on brain MRI, and creatine kinase
was 41500 IU/l. A muscle biopsy performed at 16 months iden-
tified a dystrophic process. From the developmental perspective,
he sat with support at 8 months and started to walk at 15 months.
At the age of 4 years, his head circumference was 50 cm (9th
percentile), and he had evidence of axial weakness with subgravity
neck and hip girdle power, but antigravity strength in the remain-
ing muscles. He rose from the supine position with a Gowers’ sign.
Ophthalmological examination revealed apraxic ocular movements
and head thrusts, nystagmus at the extremes of gaze and an
intermittent, alternating convergent squint. At his last clinical
evaluation at the age of 7 years, he demonstrated further im-
provements. He stood with a lordotic posture and evidence of
mild scapular winging. He rose from the floor in 1.4 s and had a
waddling-type gait. Currently he is attending mainstream school
with average academic achievements. Case 9 (Fig. 1) is a female
who presented at birth with transient hypotonia and poor feeding.
At 6 months of age, she was diagnosed with severe myopia and
strabismus. She made rapid motor progress, and was able to sit at
6 months and walk at 18 months. At the age of 10 years, she lost
the ability to rise from the floor. She is normocephalic. Her formal
cognitive function was within the normal range (IQ of 89). At the
age of 20, the examination showed paresis of superior oblique
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muscles and abducens muscles and strabismus without clear
oculomotor apraxia. She also had myopia and buphthalmos.
Currently, at 23 years of age, she can take a few steps indoors
with assistance only and has been experiencing mild swallowing
difficulties.
Brain imaging
Brain imaging was available for Cases 1, 2, 5, 6, 7, 8 and 9. Brain
magnetic resonance imaging (MRI) of Case 6 performed at 1 year
showed multiple cerebellar cysts and supratentorial white matter
Figure 1 Clinical phenotype. Top: The clinical phenotype of ISPD-related muscular dystrophy in early childhood with pseudohypertrophy
of lower limb muscles (A and B). Bottom: The disease at a later stage with marked pseudohypertrophy and ankle contractures (C, D and
E). (A) Case 4 at 1.5 years, (B) Case 5 at 2.5 years, (C) Case 1 at 15.5 years, (D and E) Case 9 at 8 years.
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changes (not shown). Case 9 had a brain MRI performed at 21 years
that demonstrated brainstem hypoplasia, cerebellar hypoplasia, dilated
fourth ventricle and evidence of bilateral buphthalmos (Fig. 3). The
findings of the brain MRIs of the remaining cases were normal.
Muscle imaging
Muscle MRI was performed in Case 2 at 19.5 years and Case 9
at 20 years. Images revealed noticeable sparing of sartorius
and gracilis muscles in both cases; sparing of the tibialis anterior
muscle was more evident in Case 1 (Fig. 2). The degree of fibro-
fatty replacement of muscle appeared to be concordant with the
clinical severity.
Muscle biopsy findings
Quadriceps muscle biopsies were performed in all cases except in
Case 3. Routine histochemical studies revealed variable degrees of
dystrophic features in all biopsies evaluated that included variation
in fibre size, increased fibrosis and evidence of myonecrosis and
regeneration. Immunolabelling with the -dystroglycan antibodies
(IIH6 and VIA4-1) was negative or severely reduced (Table 2).
However, there was evidence of preserved expression of
-dystroglycan using the core antibody (GT20ADG) in those biop-
sies in which this analysis could be performed (Cases 4, 6 and 7)
(Fig. 4). Laminin -2 expression was reduced in all cases except in
Case 5. Laminin -2 immunolabelling was reduced in some cases
(data not shown), whereas b-dystroglycan (Fig. 4) was generally
well preserved (immunolabelling was slightly uneven on some
fibres in Case 7, but no significant reduction was detected on
immunoblots) (Supplementary Figs 5 and 6).
Immunoblot analysis
Because of sample availability, a western blot analysis was possible
only in Cases 4, 5 and 7 (Supplementary Figs 5 and 6). The wheat
Figure 2 Muscle MRI. (A) The T1-weighted muscle MRI of the thigh and calf of Case 1 at 19.5 years of age. (B) The T1-weighted muscle
MRI of the thigh and calf of Case 9 at 20 years of age. There is sparing of sartorius and gracilis muscles (small arrows) in the thigh in both
patients and sparing of the tibialis anterior muscle more visible in Case 1 (large arrow). The differential degree of fatty fibrous replacement
is in concordance with the clinical severity with regards to ambulation, as Case 1 lost ambulation at 13 years, and Case 9 can still take a few
steps with assistance only at age 23 years. AL = adductor longus; AM = adductor magnus; BF = biceps femoris; EDL = extensor digitorum
longus; FDL = flexor digitorum longus; G = gracilis; GL = gastrocnemius lateralis; GM = gastrocnemius medialis; PG = peroneal group;
RF = rectus femoris; S = sartorius; SM = semi-membranosus; SO = soleus; ST = semi-tendinosus; TA = tibialis anterior; TP = tibialis pos-
terior; VL = vastus lateralis; VM = vastus medialis.
Figure 3 Brain MRI of Case 9 performed at 21 years of age,
revealing brainstem hypoplasia, cerebellar hypoplasia and dilated
fourth ventricle. (A) Sagittal T2-weighted image of the brain
demonstrating brainstem hypoplasia, cerebellar hypoplasia and
dilated fourth ventricle (arrow). (B) Axial T1-weighted image
of the brain, revealing a normal appearance of the cerebral
hemispheres. Interestingly, the temporalis muscles show some
fibro-fatty changes (arrow). (C) Coronal T1-weighted image of
the brain demonstrating dilatation of the fourth ventricle (arrow).
ISPD gene-related muscular dystrophy Brain 2013: 136; 269–281 | 275
 at U
CL Library Services on February 28, 2014
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Table 2 Mutations and pathology
Casea Age (years)
at time
of biopsy
Laminin a-2 a-dystroglycan
(glycoepitope
IIH6)
a-dystroglycan
(core 20)
Genetic
Screening
techniqueb
Variant 1c Variant 2c
1 4 Reduced on
many fibres
Negative ND Sanger Exon 8:
c.1114_1116del;
p.(Val372del)
Exon 8:
c.1114_1116del;
p.(Val372del)
2 1.5 Reduced on
many fibres
Negative ND Sanger Exon 8:
c.1114_1116del;
p.(Val372del)
Exon 8:
c.1114_1116del;
p.(Val372del)
3 F ND ND ND Sanger Exon 8:
c.1114_1116del;
p.(Val372del)
Exon 8:
c.1114_1116del;
p.(Val372del)
4 2 Reduced Traces Mild reduction Exome Exon 2: c.446C4T;
p.(Pro149Leu)
Exon 3: c.643C4T;
p.(Gln215*)
5 1 Positive (80-kDa
epitope); slight
reduction
300-kDa epitope
Many fibres
negative
(VIA4-1–
traces)
Positive Exome Exon 8:
c.1114_1116del;
p.(Val372del)
Exon 9: Het
c.1183A4T;
p.(Arg395*)
6 1.3 Reduced Many fibres
negative
Mild reduction Exome/
Sanger
Exon 1: c.2T4G;
p.(M1_R59del)
Exon 2: c.377G4A;
p.(Arg126His)
7 11 Reduced on many
fibres
Traces Positive, mild
reduction on
some fibres
Exome/
Sanger
Exon 1: c.157G4A;
p.(Ala53Thr)
Exon 9: c.1183A4T;
p.(Arg395*)
8 6 Marked reduction
on Immunoblot
Traces ND Sanger Exon 1: c.53dup;
p.(Ser19Glufs*97)
Exon 3: c.677A4G;
p.(Tyr226Cys)
9 5 ND Negative ND Exome Exon 6 to 8 duplication;
c.836-?_1119 + ?dup;
p.Val374Rfs*8
Exon 6 to 8 duplication;
c.836-?_1119 + ?dup;
p.Val374Rfs*8
a Cases 1, 2 and 3 are affected individuals from the same family. Cases 4 to 9 are all unrelated individuals.
b Screening technique used to originally identify mutation: Exome = Next Generation Sequencing Exome; Sanger = dideoxy fluorescent sequencing; Exome/
Sanger = indicate both techniques required to detect both mutations. Exon 1 of ISPD was not covered by the exome data and therefore additional Sanger sequencing of
exon 1 was necessary.
c Mutation nomenclature follows the recommended guidelines (www.hgvs.orf/mutnomen) with the nucleotide numbering based on GenBank reference sequence
NM_001101426.3. Nucleotide numbering denotes the adenosine of the annotated translation start codon as nucleotide position + 1.
Figure 4 Immunohistochemistry of muscle biopsies from cases with ISPD-related muscular dystrophy. Unfixed frozen sections of
quadriceps muscle biopsies from a control and three ISPD patients (Cases 4, 6, and 7) stained with haematoxylin and eosin (H & E) and
immunolabelled with antibodies against laminin-2 (LAMA2), b-dystroglycan (BDG), the glycosylated epitope of -dystroglycan (IIH6
ADG) and the core protein of -dystroglycan (GT20 ADG). Laminin-2 immunostaining was reduced in all ISPD cases. Although
expression of b-dystroglycan was similar to the control (see text), glycosylated -dystroglycan immunolabelling was absent in Cases 4 and
7 and severely reduced in Case 6. Core -DG (GT20ADG) was well preserved in all the cases.
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germ agglutinin-enriched lysate from the muscle biopsy of Case 5
showed -dystroglycan hypoglycosylation as suggested by the lack
of binding affinity to the glycoepitope-specific antibodies IIH6 and
VIA4-1. Western blot analysis of skeletal muscle of Cases 4 and 7
showed a profound reduction in -dystroglycan expression using
the IIH6 antibody, whereas b-dystroglycan expression was normal.
Genetics
All listed mutations are named according to reference sequence
NM_001101426.3 (Fig. 5), corresponding to the long isoform of
ISPD, which has 10 exons. Exon 3 of this long isoform is not
present in the other short isoform (NM_001101417.3). Exome
sequencing in Case 4 showed the following ISPD mutations at
the heterozygous state: g.chr7: 16255759 T4A, c.446 C4T,
causing p.Pro149Leu, which is located in exon 2 and
g.chr7:16445774 G4A, c.643 C4T, p.Gln215* in exon 3.
Exome sequencing in Case 5 showed a heterozygous premature
stop codon mutation in exon 9: g.chr7:16255759 T4A,
c.1183A4T, p.Arg395* and a heterozygous in-frame triplet dele-
tion in exon 8: g.chr7:16298017 AAAC4A, c.1114-1116delGTT,
leading to a single amino acid deletion p.Val372del. Exome
sequencing in Case 6 showed a heterozygous missense mutation
in exon 2: g.chr7:16445843 C4T, which is c.377G4A, leading to
p.Arg126His. Interestingly, the second compound heterozygous
mutation affecting the start codon in exon 1 c.2T4G, leading to
p.M1_R59del or p.M1?, was identified only by Sanger sequencing,
as exon 1 was not covered by the exome sequencing.
Exome sequencing in Case 7 revealed a heterozygous stop mu-
tation in exon 9: g.chr7:16255759 T4A, leading to c.1183 A4T
and causing p.Arg395*. The second compound heterozygous mu-
tation was found by Sanger sequencing to be c.157G4A causing
p.Ala53Thr located in exon 1. All ISPD mutations found by exome
sequencing were confirmed by Sanger sequencing.
Following the discovery of mutations in the ISPD gene by whole
exome sequencing, the original family that was mapped to
chromosome 7p21 was screened for mutations in all 10 exons
of the ISPD gene by Sanger sequencing. All the affected individ-
uals in this family (Cases 1, 2 and 3) were found to have inherited
a homozygous 3-bp deletion in exon 8 resulting in a single amino
acid deletion (c.1114-1116delGTT; p.Val372del). The mutation
was found to be co-segregating with the phenotype. In the
remaining cases, we identified one patient (Case 8) with a frame-
shift mutation (c.53dupT) in exon 1 and a missense mutation in
exon 3 c.677A4G (p.Tyr226Cys). The heterozygous carrier status
of the parents demonstrating the expected phase for an autosomal
recessive inheritance was confirmed in all families except in the
family of Case 6, as parental DNA was not available.
A read depth copy number analysis (R package ExomeDepth,
Plagnol et al., 2012) of the exome sequence from Case 9 detected
double the number of expected reads in a 40 916 kb region
[chr7:16276936–16317852 (UCSC hg19)] involving exons 6, 7
and 8 of the ISPD gene (Supplementary Fig. 2). Quantitative
fluorescent PCR analysis of genomic DNA confirmed that ISPD
exons 6, 7 and 8 were homozygously duplicated in Case 9,
resulting in an out-of-frame duplication (Supplementary Fig. 4)
and that both her parents were carriers of the mutation (data
not shown).
Discussion
Functional glycosylation defects of -dystroglycan represent a
major pathological subgroup of congenital and LGMDs. These
so-called dystroglycanopathies range from a lethal clinical variant
Figure 5 ISPD protein and mutations. The domain structure of the ISPD protein is illustrated and the corresponding exons are shown. The
darker region represents the active functionally conserved CDP-ME domain (V47–A273). Mutations found in a compound heterozygous
state are connected with a horizontal line. The small-sized horizontal bars represent the number of observed alleles. Bottom: The con-
servation of the missense mutations (marked with bold letters) within the vertebrates [Homo sapiens NP_001094896.1; Pan troglodytes
(XP_003318374.1) 99% amino acid identity; Macaca mulatta (XP_001105001.2) 94% amino acid identity; Bos taurus (XP_002686725.1)
81% amino acid identity; Canis lupus familiaris (XP_003431914.1) 84% amino acid identity; Rattus norvegicus (NP_001008387.1) 73%
amino acid identity; Mus musculus (NP_848744.1) 74% amino acid identity; Gallus gallus (XP_418693.2) 66% amino acid identity;
Xenopus tropicalis (NP_001016240.1) 60% amino acid identity; Danio rerio (NP_001071270.1) 47% amino acid identity].
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of Walker–Warburg syndrome with cerebral and ocular involve-
ment to milder forms of adult-onset LGMD such as LGMD2I
(Godfrey et al., 2007). Although each of the eight known genes
that code for putative or demonstrated glycosyltransferases or
proteins involved in the glycosylation of -dystroglycan could in
theory cause each of these clinical variants, there has been a
marked difference in frequency and clustering of phenotypes for
certain known genes so far. Mutations in FKRP are the most
common cause of dystroglycanopathy in the UK (Mercuri et al.,
2003, 2009; Poppe et al., 2003) and can cause the entire spec-
trum of dystroglycanopathy phenotypes (Brockington et al., 2002;
Brown and Winder, 2012; Devisme et al., 2012). Other genes
such as POMGNT1, POMT1 and POMT2 are mostly responsible
for phenotypes with CNS involvement (Mercuri et al., 2009;
Messina et al., 2010; Brown and Winder, 2012; Devisme et al.,
2012). The DPM3 and DOLK genes, which represent an overlap-
ping group with N-glycosylation disorders and dystroglycanopa-
thies, are rare, as only a handful of cases have been described
to date (Lefeber et al., 2009, 2011; Brown and Winder, 2012).
The genetic aetiology of this group is indeed diverse, and 50%
of the cases with dystroglycanopathy remain unsolved (Wewer
et al., 1997; Mercuri et al., 2009). After the discovery of bi-allelic
loss-of-function mutations in ISPD causing Walker–Warburg syn-
drome (Roscioli et al., 2012; Willer et al., 2012), we can now
describe the full spectrum of phenotypes caused by recessive mu-
tations in ISPD including a quite common milder allelic LGMD
phenotype. The spectrum of the phenotypes ascertained in this
study ranges from cases with congenital muscular dystrophy with-
out CNS involvement (Case 4), milder cases with LGMD without
CNS involvement (Cases 1, 2, 3, 5 and 7) (Fig. 1) and a rather
unusual and novel phenotype with relatively mild skeletal muscle
weakness manifesting as a LGMD and structural brain involvement
affecting predominantly the subtentorial structures (Cases 6 and 9)
(Fig. 1), confirming once again the preferential involvement of
subtentorial structures in dystroglycanopathies (Clement et al.,
2008). This phenotype is in contrast to LGMD2K, which is asso-
ciated with microcephaly and mental retardation (Lommel et al.,
2010), a phenotype that Case 8 in our series resembles. As an
LGMD phenotype with structural cerebellar involvement has not
been reported in any of the remaining dystroglycanopathies, this
combination of features appears to be highly evocative of an
ISPD-related muscular dystrophy. We suggest the use of the
term ‘limb-girdle muscular dystrophy with cerebellar involvement’
(LGMD-CRB) to describe these patients. This term could be added
to the recently proposed classification of dystroglycanopathies
(Godfrey et al., 2011).
As in other dystroglycanopathies, ISPD-related disease is pro-
gressive, with most cases with LGMD losing ambulation in their
early teenage years, thus following a Duchenne muscular
dystrophy-like path. In several patients, there was muscle pseudo-
hypertrophy, including the tongue. Respiratory and cardiac func-
tions also demonstrated decline, resembling that reported for other
dystroglycanopathies (Mercuri et al., 2003; Murakami et al., 2006;
Bourteel et al., 2009; Lefeber et al., 2011; Yilmaz et al., 2011).
Therefore, regular surveillance of heart function by ECG and re-
spiratory function by regular overnight polysomnography is
required in ISPD-related muscular dystrophy. Muscle MRI shows
replacement with fat and connective tissue in the lower limbs with
sparing of the semitendinosus and gracilis muscles in the thighs
and the tibialis anterior muscle in the calves. Interestingly, the
gracilis muscle is also spared in FKRP-related LGMD2I (Bourteel
et al., 2009).
From the histopathological perspective, all cases show substan-
tially reduced IIH6 or VIA4-1 labelling, indicating the loss of func-
tional -dystroglycan glycosylation. Using immunocytochemistry,
there were no clear differences in IIH6 staining between severe
and milder phenotypes in the majority of cases. The lack of cor-
relation between severity of skeletal muscle involvement and loss
of the IIH6 epitope on immunocytochemistry and immunoblot
(even after wheat germ agglutinin enrichment, Case 5) is quite
striking in ISPD-related muscular dystrophy. Variable correlations
between clinical phenotype and IIH6 content in skeletal muscle
have been reported for mutations in other genes such as FKRP
and FKTN (Jimenez-Mallebrera et al., 2009), while there appears
to be a better correlation for POMT1-, POMT2- and POMGNT1-
related dystroglycanopathies (Jimenez-Mallebrera et al., 2009;
Lommel et al., 2010). This poor correlation (i.e. apparent severe
depletion of IIH6 epitope also in patients with relatively milder
variants) may be due to the fact that there is some laminin-bind-
ing activity on -dystroglycan owing to other glycans that are not
recognized by IIH6 (McDearmon et al., 1998, 2001, 2003, 2006;
Stalnaker et al., 2010, 2011). Our genetic data (Fig. 5) demon-
strate a good genotype–phenotype correlation in the ISPD-related
muscular dystrophy. We have previously shown (Willer et al.,
2012) that bi-allelic loss-of-function mutations cause a Walker–
Warburg syndrome phenotype. Compound heterozygosity of a
missense mutation and a loss-of-function mutation affecting one
of the first five exons of ISPD results in a congenital muscular
dystrophy phenotype (Case 4), LGMD-CRB phenotype (Case 6)
or a LGMD phenotype with mental retardation (Case 8), because
the first five exons of ISPD contain the functional conserved
4-diphosphocytidyl-2-methyl-D-erythritol synthase (CDP-ME)
domain. The cases with milder LGMD without brain involvement
have either a homozygous in-frame deletion of a single amino acid
in exon 9 (p.V372del) (Cases 1, 2 and 3) or are compound het-
erozygous for a mild mutation and a stop mutation in exon 9
(Cases 5 and 7). Mutations in other domains could also alter the
function of ISPD substantially, as a homozygous stop mutation
p.Glu396* has been reported to cause a Walker–Warburg syn-
drome phenotype (Roscioli et al., 2012). The effect of the homo-
zygous duplication of exons 6, 7 and 8 in Case 9 is also
interesting. We predicted that the open reading frame would be
translated until exon 8 and followed by a frameshift in exon 9,
which could lead to a truncated ISPD protein (Val374Rfs*8). The
mild phenotype in this patient is surprising and could be accounted
for by a number of different mechanisms: (i) there could be a
splicing aberration leading to the production of reduced levels of
an in-frame message; (ii) the truncated protein could be partly
active, as the CDP-ME containing exons of ISPD are translated;
and (iii) there could be incomplete nonsense-mediated decay
related to the mutation occurring towards the 30 end of the
gene. The question that remains is how these dystroglycanopathy
phenotypes might be explained by the putative function of ISPD.
In eubacteria, green algae and chloroplasts of higher plants, ISPD
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orthologues are part of the methylerythritol pathway. This path-
way contains the CDP-ME domain and catalyzes the third step in
the alternative (non-mevalonate) pathway of isopentenyl diphos-
phate biosynthesis (isoprenoid precursor). The formation of
4-diphosphocytidyl-2C-methyl-D-erythritol from cytidine triphos-
phate and 2C-methyl-D-erythritol 4-phosphate is also called cyti-
dyltransferase activity. This mevalonate-independent pathway uses
pyruvate and glyceraldehyde 3-phosphate as starting materials for
production of isopentenyl diphosphate and occurs in a variety of
bacteria, archaea and plant cells but is absent in mammals, which
suggests that ISPD must have a different function(s) in humans.
The mechanism by which ISPD mutations lead to a reduction of
-dystroglycan glycosylation is not well understood. Apart from
the CDP-ME domain, ISPD also contains and belongs to the
glycosyltransferase-A family (Breton et al., 2006). Interestingly,
LARGE also belongs to this glycosyltransferase-A family. The func-
tion of LARGE has been partly elucidated; it acts as a bi-functional
glycosyltransferase, with both xylosyltransferase and glucuronyl-
transferase activities, attaching repeating units of [-3-xylose-1,3-
glucuronic acid-b1-] to -dystroglycan (Inamori et al., 2012).
Considering that there are also some prokaryotes that lack the
methylerythritol pathway and contain homologous enzymes such
as TarI in Streptococcus pneumonia, which synthesizes activated
CDP-ribitol (Baur et al., 2009; Roscioli et al., 2012), one could
hypothesize that in vertebrates ISPD activates nucleotide sugar
building blocks for complex -dystroglycan glycosylation or even
that it could have complex glycosyltransferase activity similar to
LARGE. However, the experimental evidence reported in our
recent study (Willer et al., 2012) suggests that in patients with
ISPD-deficient Walker–Warburg syndrome, O-mannosylation was
strongly impaired and subsequently the O-mannosyl phosphoryl-
ation and LARGE-dependent hyperglycosylation were absent
(Willer et al., 2012). This indicates the pivotal role for ISPD in
the initial step of the O-mannosylation of -dystroglycan.
Mutations in ISPD appear to be relatively common; in our pre-
vious population study (Willer et al., 2012), we evaluated 92 pa-
tients with dystroglycanopathy after exclusion of FKRP, and the
most frequent mutations found were in POMT1 and POMT2
(8.6% each). Here we have screened 47 cases, and 7 of 44
(16%) non-familial cases have mutations in ISPD. We recently
reported that 30% of the Walker–Warburg syndrome cohort
and 11% of the dystroglycanopathy cohort (Willer et al., 2012)
have ISPD mutations, similar to another report on Walker–
Warburg syndrome (Roscioli et al., 2012). The ISPD gene also
appears to be frequently affected by copy number variations
(Willer et al., 2012); therefore, testing for copy number variations
in ISPD will be essential in the diagnostic evaluation of patients
with dystroglycanopathy.
In conclusion, ISPD mutations are a common cause of secondary
dystroglycanopathy with a phenotypic spectrum ranging from
Walker–Warburg syndrome to LGMD. As the laminin-binding
glycoepitope is almost undetectable in most of the cases with
ISPD-related muscular dystrophy, the elusive function of ISPD
must have a pivotal role for functional -dystroglycan glycosyla-
tion. Uncovering of the ISPD function will help to decipher the
glycosylation pathway of -dystroglycan.
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